Details of the Drug

General Information of Drug (ID: DMK7HFI)

Drug Name

Mefenamic acid

Synonyms

ApoMefenamic; Bonabol; Contraflam; Coslan; Dysman; Lysalgo; Mefac; Mefacit; Mefedolo; Mefenacid;Mefenamate; Mefenaminsaeure; Mefic; Mycasaal; Namphen; NuMefenamic; Parkemed; Pinalgesic; Ponalar; Ponalgic; Ponmel; Ponstan; Ponstel; Ponstil; Ponstyl; Ponsyl; Pontal; Rolan; Tanston; Vialidon; APS Brand of Mefenamic Acid; Acide mefenamique; Acide mefenamique [French]; Acido mefenamico; Acidum mefenamicum; Antigen Brand of Mefenamic Acid; Apo Mefenamic; Apotex Brand of Mefenamic Acid; Ashbourne Brand of Mefenamic Acid; Chemidex Brand of Mefenamic Acid; Clonmel Brand of Mefenamic Acid; Elan Brand of Mefenamic Acid; Farmasierra Brand of Mefenamic Acid; First Horizon Brand of Mefenamic Acid; Godecke Brand of Mefenamic Acid; Mefanamic acid; Mefenaminic Acid; Mefenaminsaeure [German]; Mephenamic acid; Mephenaminic acid; Methenamic acid; Nu Mefenamic; Nu Pharm Brand of Mefenamic Acid; PMS Mefenamic Acid; Parke Davis Brand of Mefenamic Acid; Pfizer Brand of Mefenamic Acid; Pharmascience Brand of Mefenamic Acid; Pinewood Brand of Mefenamic Acid; Ponstan forte; Rowa Brand of Mefenamic Acid; Tamany Bonsan; Warner Lambert Brand of Mefenamic Acid; CL 473; CN 35355; HL 1; ID8; INF 3355; M1782; AGN-1255; Ac. mefenamico; Ac. mefenamico [Italian]; Acid, Mefenamic; Acid, Mefenaminic; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Apo-Mefenamic; Bafameritin-M; Bafhameritin-M; CN-35355; Dyfenamic (TN); F0850-6853; Forte, Ponstan; INF-3355; In-M; Mafepain (TN); Meftal (TN); Mephadolor (TN); Nu-Mefenamic; Nu-Pharm Brand of Mefenamic Acid; PMS-Mefenamic Acid; Parkemed (TN); Ponstal (TN); Ponstan (TN); Ponstel (TN); Potarlon (TN); Warner-Lambert Brand of Mefenamic Acid; Mefenamic acid (JP15/USP/INN); Mefenamic acid [USAN:INN:BAN:JAN]; N-2,3-Xylylanthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; 2-(2,3-Dimethylanilino)benzoic acid; 2-(2,3-Xylidino)benzoic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; 2-[(2,3-dimethylphenyl)amino]benzoic acid

Indication

Disease Entry	ICD 11	Status	REF
Dysmenorrhea	GA34.3	Approved	[1], [2], [3]

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

241.28

Topological Polar Surface Area (xlogp)

5.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 90% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The apparent oral clearance of drug is 21.23 L/h [6]
Elimination: 1% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 hours [7]
Metabolism: The drug is metabolized via the CYP2C9 to 3-hydroxymethyl mefenamic acid [8]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 74.007 micromolar/kg/day [9]
Vd: The volume of distribution (Vd) of drug is 1.06 L/kg [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.08 mg/mL [4]

Chemical Identifiers

Formula: C15H15NO2
IUPAC Name: 2-(2,3-dimethylanilino)benzoic acid
Canonical SMILES: CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C
InChI: InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
InChIKey: HYYBABOKPJLUIN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4044
ChEBI ID: CHEBI:6717
CAS Number: 61-68-7
DrugBank ID: DB00784
TTD ID: D05FTJ
VARIDT ID: DR00533
INTEDE ID: DR1014
ACDINA ID: D00390

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[11]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[12]
Cytochrome P450 102A1 (cyp102)	DE4OGUF	CPXB_BACMB	Substrate	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Dysmenorrhea

ICD Disease Classification

GA34.3

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	7.93E-04	-0.29	-0.34
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.82E-04	-1.35E-01	-5.84E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mefenamic acid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Mefenamic acid and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[41]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Mefenamic acid and Repaglinide.	Acute diabete complication [5A2Y]	[42]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Mefenamic acid and Glibenclamide.	Acute diabete complication [5A2Y]	[42]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Mefenamic acid and Tolazamide.	Acute diabete complication [5A2Y]	[42]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Mefenamic acid and Glipizide.	Acute diabete complication [5A2Y]	[42]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Mefenamic acid caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[43]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Inotersen.	Amyloidosis [5D00]	[43]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Mefenamic acid and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[44]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Cilostazol.	Arterial occlusive disease [BD40]	[45]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Mefenamic acid and Budesonide.	Asthma [CA23]	[46]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Mefenamic acid and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[47]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Kanamycin.	Bacterial infection [1A00-1C4Z]	[48]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS stimulant effects by the combination of Mefenamic acid and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[47]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Streptomycin.	Bacterial infection [1A00-1C4Z]	[48]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Mefenamic acid and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[47]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Mefenamic acid and ABT-492.	Bacterial infection [1A00-1C4Z]	[47]
Gentamicin	DMKINJO	Moderate	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Gentamicin.	Bacterial infection [1A00-1C4Z]	[48]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Netilmicin.	Bacterial infection [1A00-1C4Z]	[48]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Mefenamic acid and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[47]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS stimulant effects by the combination of Mefenamic acid and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[47]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Mefenamic acid and Etidronic acid.	Bone paget disease [FB85]	[49]
Risedronate	DM5FLTY	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Mefenamic acid and Risedronate.	Bone paget disease [FB85]	[49]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Mefenamic acid caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[50]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Mefenamic acid caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[51]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[45]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Iodipamide.	Cholelithiasis [DC11]	[52]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Levomilnacipran.	Chronic pain [MG30]	[53]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Mefenamic acid and Regorafenib.	Colorectal cancer [2B91]	[43]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Mefenamic acid and Drospirenone.	Contraceptive management [QA21]	[54]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Mefenamic acid and Ardeparin.	Coronary thrombosis [BA43]	[55]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Mefenamic acid caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[56]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Mefenamic acid caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[57]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Mefenamic acid caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[58]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Mefenamic acid caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[59]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Mefenamic acid and Danaparoid.	Deep vein thrombosis [BD71]	[55]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Mefenamic acid and Rivaroxaban.	Deep vein thrombosis [BD71]	[60]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Sertraline.	Depression [6A70-6A7Z]	[53]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Vilazodone.	Depression [6A70-6A7Z]	[53]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Vortioxetine.	Depression [6A70-6A7Z]	[53]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Milnacipran.	Depression [6A70-6A7Z]	[53]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Escitalopram.	Depression [6A70-6A7Z]	[53]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Desvenlafaxine.	Depression [6A70-6A7Z]	[53]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and PMID28870136-Compound-49.	Discovery agent [N.A.]	[61]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Mefenamic acid and Cannabidiol.	Epileptic encephalopathy [8A62]	[43]
Ethacrynic acid	DM60QMR	Moderate	Antagonize the effect of Mefenamic acid when combined with Ethacrynic acid.	Essential hypertension [BA00]	[62]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Tazemetostat.	Follicular lymphoma [2A80]	[45]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Mefenamic acid and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[43]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Sulfinpyrazone.	Gout [FA25]	[45]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Mefenamic acid when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[62]
Bumetanide	DMRV7H0	Moderate	Antagonize the effect of Mefenamic acid when combined with Bumetanide.	Heart failure [BD10-BD1Z]	[62]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Mefenamic acid caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[63]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Mefenamic acid and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[64]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Mefenamic acid caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Mefenamic acid caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[41]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Mefenamic acid and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[66]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Mefenamic acid and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[67]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Mefenamic acid and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[68]
Indapamide	DMGN1PW	Moderate	Antagonize the effect of Mefenamic acid when combined with Indapamide.	Hypertension [BA00-BA04]	[62]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Mefenamic acid when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[62]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Mefenamic acid when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[69]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Dipyridamole.	Hypertension [BA00-BA04]	[45]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Mefenamic acid caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[41]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[70]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Mefenamic acid and Idelalisib.	Mature B-cell leukaemia [2A82]	[71]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Mefenamic acid and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[72]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Mefenamic acid and Ibrutinib.	Mature B-cell lymphoma [2A85]	[73]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Mefenamic acid and Ponatinib.	Mature B-cell lymphoma [2A85]	[74]
Arry-162	DM1P6FR	Moderate	Decreased metabolism of Mefenamic acid caused by Arry-162 mediated inhibition of UGT.	Melanoma [2C30]	[41]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Mefenamic acid caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[43]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Exjade.	Mineral absorption/transport disorder [5C64]	[75]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Mefenamic acid and Panobinostat.	Multiple myeloma [2A83]	[41]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Mefenamic acid and Deflazacort.	Muscular dystrophy [8C70]	[46]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[45]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Mefenamic acid and Dasatinib.	Myeloproliferative neoplasm [2A20]	[76]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Mefenamic acid and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[77]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Mefenamic acid and Prasugrel.	Myocardial infarction [BA41-BA43]	[43]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Mefenamic acid and Vorapaxar.	Myocardial infarction [BA41-BA43]	[78]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Sibutramine.	Obesity [5B80-5B81]	[53]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Dexfenfluramine.	Obesity [5B80-5B81]	[53]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Mefenamic acid when combined with Polythiazide.	Oedema [MG29]	[62]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Mefenamic acid caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[79]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and MK-4827.	Ovarian cancer [2C73]	[43]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Mefenamic acid and Aspirin.	Pain [MG30-MG3Z]	[80]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Mefenamic acid caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[81]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Epoprostenol.	Pulmonary hypertension [BB01]	[82]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Iloprost.	Pulmonary hypertension [BB01]	[82]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Everolimus.	Renal cell carcinoma [2C90]	[83]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Temsirolimus.	Renal cell carcinoma [2C90]	[83]
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Sulfasalazine.	Rheumatoid arthritis [FA20]	[84]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Mefenamic acid and Dexamethasone.	Rheumatoid arthritis [FA20]	[46]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Mefenamic acid and Leflunomide.	Rheumatoid arthritis [FA20]	[67]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Mefenamic acid and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[46]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Mefenamic acid and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[43]
Prednisolone	DMQ8FR2	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Mefenamic acid and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[46]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Mefenamic acid and Pitolisant.	Somnolence [MG42]	[43]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Caplacizumab.	Thrombocytopenia [3B64]	[45]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Mefenamic acid and Apixaban.	Thrombosis [DB61-GB90]	[43]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Cangrelor.	Thrombosis [DB61-GB90]	[45]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Mefenamic acid and Brilinta.	Thrombosis [DB61-GB90]	[43]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Mefenamic acid and Cabozantinib.	Thyroid cancer [2D10]	[85]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Sirolimus.	Transplant rejection [NE84]	[83]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Tacrolimus.	Transplant rejection [NE84]	[83]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Mefenamic acid and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[42]
Dapagliflozin	DM28UJG	Minor	Decreased metabolism of Mefenamic acid caused by Dapagliflozin mediated inhibition of UGT.	Type 2 diabetes mellitus [5A11]	[86]
Cinoxacin	DM4EWNS	Moderate	Additive CNS stimulant effects by the combination of Mefenamic acid and Cinoxacin.	Urinary tract infection [GC08]	[47]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Mefenamic acid and Plazomicin.	Urinary tract infection [GC08]	[48]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Mefenamic acid and Betrixaban.	Venous thromboembolism [BD72]	[87]
-----------


⏷ Show the Full List of 107 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 21 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Mefenamic acid 250 mg capsule	250 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2593).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 015034.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
9	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10	Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids. 1998 Jul;59(1):55-62.
11	Cytochrome P450-mediated bioactivation of mefenamic acid to quinoneimine intermediates and inactivation by human glutathione S-transferases. Chem Res Toxicol. 2014 Dec 15;27(12):2071-81.
12	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
13	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
14	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
15	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
16	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
17	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
18	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
19	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
20	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
21	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
22	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
23	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
24	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
25	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
26	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
27	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
28	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
29	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
30	acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
31	Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
32	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
33	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
34	Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
35	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
36	Pfizer. Product Development Pipeline. March 31 2009.
37	Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
38	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
39	Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
40	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
41	Cerner Multum, Inc. "Australian Product Information.".
42	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
43	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
44	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
45	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
46	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
47	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
48	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
49	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
50	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
51	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
52	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
53	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
54	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
55	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
56	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
57	Cerner Multum, Inc. "Canadian Product Information.".
58	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
59	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
60	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
61	Canadian Pharmacists Association.
62	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
63	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
64	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
65	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
66	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
67	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
68	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
69	McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
70	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
71	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
72	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
73	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
74	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
75	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
76	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
77	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
78	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
79	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
80	Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
81	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
82	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
83	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
84	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
85	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
86	Product Information. Farxiga (dapagliflozin). Bristol-Myers Squibb, Princeton, NJ.
87	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.